COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

CI-1040 in Treating Patients With Advanced Breast, Colon, Pancreatic, or Non-Small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00033384
Recruitment Status : Completed
First Posted : July 8, 2003
Last Update Posted : April 12, 2013
National Cancer Institute (NCI)
Information provided by (Responsible Party):
University of Alabama at Birmingham

Brief Summary:

RATIONALE: CI-1040 may stop the growth of tumors by blocking the enzymes necessary for cancer cell growth and by stopping blood flow to the tumor.

PURPOSE: Phase II trial to study the effectiveness of CI-1040 in treating patients who have metastatic or unresectable breast, colon, pancreatic, or non-small cell lung cancer.

Condition or disease Intervention/treatment Phase
Breast Cancer Colorectal Cancer Lung Cancer Pancreatic Cancer Drug: CI-1040 Phase 2

Detailed Description:


  • Determine the antitumor activity of CI-1040 in patients with non-small cell lung, breast, colon, or pancreatic cancer.
  • Determine the safety profile of this drug in these patients.
  • Assess quality of life (overall and for each tumor type) of patients treated with this drug.
  • Determine the relationship between study drug concentration and antitumor response in these patients and target suppression and safety of this drug.
  • Correlate target suppression (pERK) with antitumor effects of this drug in these patients.
  • Correlate the mRNA expression profile of the tumors with antitumor effects of this drug in these patients.

OUTLINE: This is a multicenter study. Patients are stratified according to tumor type (non-small cell lung vs breast vs colon vs pancreas).

Patients receive oral CI-1040 twice daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Quality of life is assessed at baseline and then every 28 days during the first 6 months of study therapy.

Patients are followed every 2 months.

PROJECTED ACCRUAL: A total of 52-172 patients (13-43 per stratum) will be accrued for this study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Primary Purpose: Treatment
Official Title: A Multicenter Phase 2 Study of CI-1040 In Patients With Advanced Nonsmall-Cell Lung Cancer, Breast Cancer, Colon Cancer Or Pancreatic Cancer
Study Start Date : February 2002
Actual Primary Completion Date : November 2003
Actual Study Completion Date : November 2003

Resource links provided by the National Library of Medicine

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically or cytologically confirmed metastatic or inoperable non-small cell lung, breast, or colon cancer or duct cell carcinoma of the exocrine pancreas
  • Bidimensionally measurable lesions that are not previously irradiated

    • New lesions that have developed in a previously irradiated field may be used as measurable disease
  • No brain metastases

    • Patients with prior brain metastases are allowed provided they have undergone prior resection of metastases and/or 1 prior course of cranial irradiation, have no new sites of brain metastases since then, have no worsening CNS symptoms, and have discontinued prior corticosteroids for at least 30 days
  • Hormone receptor status:

    • Not specified



  • 18 and over


  • Not specified

Menopausal status:

  • Not specified

Performance status:

  • ECOG 0-2

Life expectancy:

  • Not specified


  • Absolute neutrophil count at least 1,500/mm^3
  • Platelet count at least 100,000/mm^3


  • Bilirubin no greater than 2 times upper limit of normal (ULN)
  • AST or ALT no greater than 2 times ULN (5 times ULN if due to liver involvement)


  • Creatinine no greater than 1.5 times ULN


  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for 30 days after study participation
  • Capable of swallowing intact study medication capsules
  • Capable of following instructions regarding study medication or has daily caregiver to administer study medication
  • No concurrent serious infection
  • No life-threatening illness unrelated to tumor
  • No other prior or concurrent malignancy within the past 3 years except nonmelanoma skin cancer or carcinoma in situ of the cervix


Biologic therapy:

  • At least 2 weeks since prior immunotherapy or biologic therapy


  • At least 4 weeks since prior cytotoxic chemotherapy
  • No more than 1 prior cytotoxic chemotherapy regimen for metastatic non-small cell lung or colon cancer
  • No more than 2 prior cytotoxic chemotherapy regimens for breast cancer
  • No prior cytotoxic chemotherapy for pancreatic cancer

Endocrine therapy:

  • See Disease Characteristics
  • At least 2 weeks since other prior hormonal therapy


  • See Disease Characteristics
  • At least 3 weeks since prior radiotherapy and recovered
  • No concurrent radiotherapy


  • See Disease Characteristics


  • No other concurrent anticancer agents

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00033384

Layout table for location information
United States, Alabama
University of Alabama at Birmingham Comprehensive Cancer Center
Birmingham, Alabama, United States, 35294-3300
Sponsors and Collaborators
University of Alabama at Birmingham
National Cancer Institute (NCI)
Layout table for investigator information
Study Chair: John J. Rinehart, MD University of Alabama at Birmingham
Layout table for additonal information
Responsible Party: University of Alabama at Birmingham Identifier: NCT00033384    
Other Study ID Numbers: CDR0000069279
First Posted: July 8, 2003    Key Record Dates
Last Update Posted: April 12, 2013
Last Verified: December 2002
Keywords provided by University of Alabama at Birmingham:
stage III colon cancer
stage IV colon cancer
stage IV breast cancer
stage IIIA breast cancer
recurrent breast cancer
stage IIIB breast cancer
recurrent non-small cell lung cancer
stage II pancreatic cancer
stage III pancreatic cancer
recurrent pancreatic cancer
recurrent colon cancer
stage IIIA non-small cell lung cancer
stage IIIB non-small cell lung cancer
stage IV non-small cell lung cancer
duct cell adenocarcinoma of the pancreas
stage IV pancreatic cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Lung Neoplasms
Pancreatic Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms
Lung Diseases
Respiratory Tract Diseases
Digestive System Neoplasms
Digestive System Diseases
Endocrine Gland Neoplasms
Pancreatic Diseases
Endocrine System Diseases